COPENHAGEN, May 6 /PRNewswire/ --

- Zendesk's help desk in the cloud brings tender loving customer care to 1,000 organizations

HOUSTON and BARCELONA, Spain, May 6 /PRNewswire/ --

On Tuesday, May 5, 2009, Fractus S.A. of Barcelona, Spain sued cell phone manufacturers Samsung, LG, RIM, Pantech, Kyocera, Palm, HTC, Sharp, UTStarcom, and Sanyo for infringing nine different patents held by Fractus.

Fractus is an early pioneer in developing internal antennas for cellular phones and other industries. Founded in 1999, Fractus set out to meet the challenge of delivering antennas small enough to fit inside a cell phone yet powerful enough to support today's multiband cell phones. Fractus has been, and remains, an active supplier of antennas and has shipped millions of antennas worldwide.

MUMBAI, May 6 /PRNewswire/ -- A Process Training program Developed by Tata Interactive Systems (TIS) was recently short-listed in the Best e-learning program category at the Training Journal (TJ) Awards 2009.

TIS' program to facilitate Micronutrient Initiative (MI) and World Food Programme's (WFP) initiative to eradicate iodine deficiency through structured training on salt quality for salt manufacturers across Africa was short-listed in the Best e-learning program category at the Training Journal (TJ) Awards.

The TJ Awards follow the TJ Conference, which selects the top twelve names from all sections of the learning industry including HR, LD, Diversity, Coaching, Training, and Corporate organizations.

STOCKHOLM, May 6 /PRNewswire/ -- Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease. The results showed that a single-day dosing of AXL1717 could be successfully escalated with excellent tolerability. No dose-limiting toxicity was reported. The next part of the trial has now been approved, including a seven-day dosing BID regimen instead of single-day BID treatments. The first patients have already been treated with AXL1717 for seven days.

REHOVOT, Israel, May 6 /PRNewswire/ -- D-Pharm announced today that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for its pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients. D-Pharm plans to initiate the trial later this year following FDA review of the IND and SPA. Recently, D-Pharm also obtained Scientific Advice from the European Medicines Agency (EMEA) on the development strategy for DP-b99 in Europe.

CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the signature of an exclusive and worldwide licence agreement on July 10th 2008 with the University of Bordeaux. The contract covers the development, production and marketing of a paediatric beta-blocker for the treatment of severe infantile haemangioma with the intention of obtaining NDA-approval (New Drug Application) both for Europe and the USA. Patents were also applied for in this indication.

CALGARY, Canada, May 6 /PRNewswire/ -- Addax Petroleum Corporation (TSX: AXC and LSE: AXC) (Addax Petroleum or the Corporation) will announce its financial results for the quarter ended March 31, 2009 on Wednesday, May 13, 2009, and will discuss its financial results in a conference call on Wednesday, May 13, 2009 at 11:00 a.m. Eastern Time / 4:00 p.m. London, U.K. time. Mr. Jean Claude Gandur, President and Chief Executive Officer, Mr. James Pearce, Chief Operating Officer, and Mr. Michael Ebsary, Chief Financial Officer, will discuss the Corporation's most recent financial and operating results.

LONDON, May 6 /PRNewswire/ --

Analog screening systems are gradually being replaced by digital mammography systems. Screening programmes for breast cancer detection are responsible for driving the market. A majority of screening programmes have already been implemented in European countries. However, in some others, implementation of these programmes is proceeding slowly but steadily, leading to the increased installation of mammography systems.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

LONDON, May 6 /PRNewswire/ -- Micro Focus is set to attain a leading position in the Automated Software Quality market, with recommended offers to acquire both Borland Software Corporation and a division of Compuware.

Stephen Kelly, Micro Focus Chief Exectuive, said the move was a very logical progression for the company and built on the products Micro Focus already offered in the testing space - a market valued at $2bn annually.

The deals will be part funded with a credit facility backed by HSBC, Barclays, Lloyds and RBS. The CEO defended the decision to stretch the company despite the economic backdrop:

CALGARY, Canada, May 6 /PRNewswire/ -- PENN WEST ENERGY TRUST (TSX - PWT.UN; NYSE - PWE) is pleased to announce its results for the first quarter ended March 31, 2009